Uliginosin B presents antinociceptive effect mediated by dopaminergic and opioid systems in mice.
Prog Neuropsychopharmacol Biol Psychiatry
; 39(1): 80-7, 2012 Oct 01.
Article
in En
| MEDLINE
| ID: mdl-22627196
ABSTRACT
Previous studies have shown that uliginosin B inhibits dopamine reuptake in rat brain. This compound occurs in Hypericum polyanthemum and H. caprifoliatum for which was reported to have antinociceptive effect sensitive to naloxone. The aim of this study was to assess the antinociceptive effect of uliginosin B and to evaluate the involvement of opioid and dopaminergic receptors activation. Uliginosin B presented antinociceptive effect in hot-plate and abdominal writhing tests, in mice, at doses that did not impair the motor coordination (15 mg/kg, i.p.). Uliginosin B in high dose (90 mg/kg, i.p.) presented ataxic effect in the rotarod apparatus. These effects seem to be mediated by distinct receptors since the effect on the hot-plate was completely abolished by naloxone and sulpiride, but it was unaffected by SCH 23390. On the other hand, the motor impairment induced by uliginosin B was completely prevented by naloxone and partially prevented by sulpiride and SCH 23390. However, the receptors' activation appears to be indirect since uliginosin B did not bind to opioid and dopaminergic receptors. Thus, uliginosin B effects probably are due to its ability to inhibit monoamine reuptake with consequent activation of dopamine receptors and indirect stimulation of opioid system.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phloroglucinol
/
Receptors, Dopamine
/
Receptors, Opioid
/
Analgesics
Limits:
Animals
Language:
En
Journal:
Prog Neuropsychopharmacol Biol Psychiatry
Year:
2012
Document type:
Article
Affiliation country:
Brazil